The Research Working Group seeks to bridge the missing mile between basic research and the commercialization of products. Having an equal partnership between the Virtual Physiological Human Institute (VPH) and industries engaged in predictive medicine provides a unique opportunity to explore areas of mutual cooperation and benefit.

The key goals of this group are:

  • Promotion of in silico medicine in Horizon 2020;
  • Working towards the creation of a Public Private Partnership (PPP) on in silico medicine;
  • Creating links between the VPH Membership and Avicenna Industry Members


Priorities in 2018

→ Further develop a comprehensive position for Avicenna on what is needed in EU research;
→ Launch of the new Avicenna Alliance internship scheme;
→ A core focus of the VPH membership is on the FET Flagship on ageing and on shaping this Flagship programme;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Working group leader:

  • Liesbet Geris
  • Executive Director, VPH Institute
  • Professor, University of Liège & KU Leuven (Belgium)

Avicenna Alliance news

Dassault to enhance clinical tech with Medidata acquisition

Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to...

find out more ›

Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025

The European Medicine Agency (EMA) has recently published a document that describes its strategy until 2025....

find out more ›

European Strategy for High Performance Computing

On the 17 June, the European Commission published a presentation explaining why they indicated High Performance Computing (HPC) as a priority area for...

find out more ›

Show all activites